FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Chinas Jinan Jinda Cited for API Deviations

FDA warns Chinas Jinan Jinda Pharmaceutical Chemistry Co. about CGMP deviations in its production of active pharmaceutical ingredients.

Medical Devices

FDA Agrees that BIA-ALCL is Rare T-Cell Lymphoma

FDA says it concurs with the World Health Organization that breast implant-associated anaplastic large cell lymphoma is a rare T-cell lymphoma that ca...

Human Drugs

FDA Approves Newron Parkinsons Drug

FDA approves a Newron Pharmaceuticals NDA for Xadago (safinamide) tablets as an add-on treatment for patients with Parkinsons disease who are currentl...

Human Drugs

Law Professor Argues for Conditional Drug Approvals

Law professor Robert Bohrer makes the case for a conditional drug approval process that would bring drugs to patients faster and at a discounted price...

Human Drugs

Orphan Drug Status for NantKwest Killer Cell Therapy

FDA grants NantKwest an orphan drug designation for the companys activated natural killer cell therapy for treating patients with advanced Merkel cell...

Human Drugs

Latest FDA Warning Letters

FDA releases its latest batch of Warning Letters that cite ARK Bio-Medical, Jinan Jinda Pharmaceutical, and USV Private Limited.

Human Drugs

FDA Denies Probiotic Suppository Petition

FDA denies a ProbioTech petition asking it to take steps to amend the dietary supplement definition so that a probiotic suppository could be considere...

Califf Wants More Clinical Trial Education

Former FDA commissioner Robert Califf says transformational progress of the clinical trials enterprise is in sight and will be aided by more education...

Federal Register

FDA Comments Sought on Custom Device Reporting

Federal Register Notice: FDA seeks comments on an information collection extension for Annual Reporting for Custom Device Exemption.

Human Drugs

Drug Design Defect Cases Still Not Settled

Attorney Eric Alexander says a Mississippi federal court decision clouds courts treatment of drug design defect claims as preempted by federal law.